Efficacy and safety of dapagliflozin on kidney and cardiovascular outcomes by baseline albuminuria: a secondary analysis of the DAPA-CKD trial

被引：0

作者：

Heerspink, H. J. Lambers ^{[1
]}

Waijer, S. W. ^{[1
]}

Vart, P. ^{[1
]}

Cherney, D. Z. I. ^{[2
]}

Chertow, G. ^{[3
]}

Langkilde, A. M. ^{[4
]}

McMurray, J. J. V. ^{[5
]}

Rossing, P. ^{[6
]}

Correa-Rotter, R. ^{[7
]}

Stefansson, B. V. ^{[4
]}

Toto, R. ^{[8
]}

Wheeler, D. ^{[9
]}

机构：

[1] Univ Med Ctr Groningen, Groningen, Netherlands

[2] Univ Toronto, Toronto, ON, Canada

[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[4] AstraZeneca, Gothenburg, Sweden

[5] Univ Glasgow, Glasgow, Lanark, Scotland

[6] Steno Diabet Ctr, Copenhagen, Denmark

[7] Natl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, Mexico

[8] UCL, Dept Internal Med, London, England

[9] UCL, Dept Renal Med, London, England

来源：

DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：30 / 30

页数：1

共 50 条

[1] Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
Persson, Frederik
Rossing, Peter
Vart, Priya
Chertow, Glenn M.
Hou, Fan Fan
Jongs, Niels
McMurray, John J., V
Correa-Rotter, Ricardo
Bajaj, Harpreet S.
Stefansson, Bergur, V
Toto, Robert D.
Langkilde, Anna Maria
Wheeler, David C.
Heerspink, Hiddo J. L.
DIABETES CARE, 2021, 44 (08) : 1894 - 1897
[2] Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial
Persson, Frederik
Rossing, Peter
Vart, Priya
Chertow, Glenn M.
Hou, Fan Fan
McMurray, John J.
Correa-Rotter, Ricardo
Bajaj, Harpreet S.
Stefansson, Bergur
Toto, Robert D.
Langkilde, Anna Maria
Wheeler, David C.
Heerspink, Hiddo L.
DIABETES, 2021, 70
[3] Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
Waijer, Simke W.
Vart, Priya
Cherney, David Z., I
Chertow, Glenn M.
Jongs, Niels
Langkilde, Anna Maria
Mann, Johannes F. E.
Mosenzon, Ofri
McMurray, John J., V
Rossing, Peter
Correa-Rotter, Ricardo
Stefansson, Bergur, V
Toto, Robert D.
Wheeler, David C.
Heerspink, Hiddo J. L.
DIABETOLOGIA, 2022, 65 (07) : 1085 - 1097
[4] Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial
Persson, Frederik
Rossing, Peter
Vart, Priya
Chertow, Glenn M.
Hou, Fan Fan
McMurray, John J.
Correa-Rotter, Ricardo
Bajaj, Harpreet S.
Stefansson, Bergur
Toto, Robert D.
Langkilde, Anna Maria
Wheeler, David C.
Heerspink, Hiddo L.
DIABETES, 2021, 70
[5] Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
Simke W. Waijer
Priya Vart
David Z. I. Cherney
Glenn M. Chertow
Niels Jongs
Anna Maria Langkilde
Johannes F. E. Mann
Ofri Mosenzon
John J. V. McMurray
Peter Rossing
Ricardo Correa-Rotter
Bergur V. Stefansson
Robert D. Toto
David C. Wheeler
Hiddo J. L. Heerspink
Diabetologia, 2022, 65 : 1085 - 1097
[6] The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
Wheeler, David C.
Stefansson, Bergur, V
Batiushin, Mikhail
Bilchenko, Oleksandr
Cherney, David Z., I
Chertow, Glenn M.
Douthat, Walter
Dwyer, Jamie P.
Escudero, Elizabeth
Pecoits-Filho, Roberto
Furuland, Hans
Gorriz, Jose Luis
Greene, Tom
Haller, Hermann
Hou, Fan Fan
Kang, Shin-Wook
Isidto, Rey
Khullar, Dinesh
Mark, Patrick B.
McMurray, John J., V
Kashihara, Naoki
Nowicki, Michal
Persson, Frederik
Correa-Rotter, Ricardo
Rossing, Peter
Toto, Robert D.
Umanath, Kausik
Van Bui, Pham
Wittmann, Istvan
Lindberg, Magnus
Sjostrom, C. David
Langkilde, Anna Maria
Heerspink, Hiddo J. L.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 (10) : 1700 - 1711
[7] DAPA-CKD: A Regional Analysis of Kidney and Cardiovascular Outcomes
Correa-Rotter, Ricardo
Vart, Priya
Jongs, Niels
Hou, Fan Fan
Chertow, Glenn M.
Langkilde, Anna Maria
McMurray, John
Rossing, Peter
Sjostrom, David
Stefansson, Bergur V.
Toto, Robert D.
Douthat, Walter
Escudero, Elizabeth T.
Isidto, Rey A.
Khullar, Dinesh
Bajaj, Harpreet S.
Wheeler, David C.
Heerspink, Hiddo J. L.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 724 - 724
[8] Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
Wheeler, David C.
Jongs, Niels
Stefansson, Bergur, V
Chertow, Glenn M.
Greene, Tom
Hou, Fan Fan
Langkilde, Anna Maria
McMurray, John J., V
Rossing, Peter
Nowicki, Michal
Wittmann, Istvan
Correa-Rotter, Ricardo
Sjostrom, C. David
Toto, Robert D.
Heerspink, Hiddo J. L.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (09) : 1647 - 1656
[9] Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study
Persson, Frederik
Rossing, Peter
Jongs, Niels
Chertow, Glenn M.
Hou, Fan Fan
Vart, Priya
McMurray, John J.
Correa-Rotter, Ricardo
Stefansson, Bergur
Toto, Robert D.
Langkilde, Anna Maria
Wheeler, David C.
Heerspink, Hiddo L.
DIABETES, 2022, 71
[10] Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
Beernink, Jelle M.
Persson, Frederik
Jongs, Niels
Laverman, Gozewijn D.
Chertow, Glenn M.
McMurray, John J. V.
Langkilde, Anna Maria
Correa-Rotter, Ricardo
Rossing, Peter
Sjostrom, C. David
Toto, Robert D.
Wheeler, David C.
Heerspink, Hiddo J. L.
DIABETES CARE, 2023, 46 (03) : 602 - 607

← 1 2 3 4 5 →